An SEC filing shows an activist investor is building a sizable position in the company.
News & Analysis: Ironwood Pharmaceuticals
IRWD earnings call for the period ending March 31, 2019.
The constipation kingpin reported fourth-quarter results that sparked investor interest.
IRWD earnings call for the period ending December 31, 2018.
Novartis may be on track to win FDA approval of a sickle disease drug before Ironwood.
A safety scare during a clinical trial with the company's lead candidate was the culprit.
New competition could slow prescription growth for Linzess and take some of the luster off this small-cap biotech stock.
Has the success of Synergy Pharmaceuticals' plecanatide put Ironwood on the warpath?
A first-quarter earnings report packed with good news, and a well-received investor presentation, caused shares to move higher in May.
Investors are cheering ahead of an upcoming presentation for its lead product candidate at a key industry conference.